NPY and type 2 diabetes mellitus: Glibenclamide (used to treat type 2 diabetes mellitus) promoted the release of NPY from hamster insulinoma tumor cells [204], and NPY blocked insulin release in the insulinoma RIN 5AH cell line; the latter action was due to the Y1R/adenylyl cyclase inhibition [205].